Clinical Trial Update: ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies [Phase 1]

View source ↗

Summary

A Phase 1 study is evaluating ICP-248 in combination with azacitidine for myeloid malignancies, including acute myeloid leukemia and myelodysplastic syndromes, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• ICP-248

Snippet

Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. | Conditions: Acute Myelogenous Leukemia, Myelodysplastic Syndromes (MDS) | Phase 1 | Status: RECRUITING